Reviews
Systematic reviews
Search a topic, title, author or review id. The Findings tab shows what the reviews found for the same words, grouped by question; the Studies tab shows the primary studies they include.
12 reviews, newest first
alemtuzumab versus interferon beta 1a for relapsing‐remitting multiple sclerosis
Cochraneheadline outcomes only
13 findings
Intravesical Bacillus Calmette‐Guérin with interferon‐alpha versus intravesical Bacillus Calmette‐Guérin for treating non‐muscle‐invasive bladder cancer
Cochraneheadline outcomes only
10 findings
Interferons‐beta versus glatiramer acetate for relapsing‐remitting multiple sclerosis
Cochraneheadline outcomes only
7 findings
Type I interferons for induction of remission in ulcerative colitis
Cochraneheadline outcomes only
4 findings
Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C
Cochraneheadline outcomes only
3 findings
Peginterferon alpha‐2a versus peginterferon alpha‐2b for chronic hepatitis C
Cochraneheadline outcomes only
7 findings
Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C
Cochraneheadline outcomes only
2 findings
Interferon alpha for the adjuvant treatment of cutaneous melanoma
Cochraneheadline outcomes only
2 findings
Interferon after surgery for women with advanced (Stage II‐IV) epithelial ovarian cancer
Cochraneheadline outcomes only
10 findings
Interferon beta for secondary progressive multiple sclerosis
Cochraneheadline outcomes only
4 findings
Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow‐responder adult patients
Cochraneheadline outcomes only
7 findings
Interferon Beta for Primary Progressive Multiple Sclerosis
Cochraneheadline outcomes only
5 findings